vs
Side-by-side financial comparison of Bone Biologics Corp (BBLG) and SMITH & NEPHEW PLC (SNN). Click either name above to swap in a different company.
Bone Biologics Corp is a clinical-stage biotechnology firm focused on developing orthobiologic products to boost bone regeneration and healing for orthopedic surgery patients, including spinal fusion recipients. It mainly operates in the U.S. healthcare market, targeting orthopedic care and regenerative medicine segments.
Smith & Nephew plc, also known as Smith+Nephew, is a British multinational medical equipment manufacturing company headquartered in Watford, England. It is an international producer of advanced wound management products, arthroscopy products, trauma and clinical therapy products, and orthopaedic reconstruction products. Its products are sold in over 100 countries. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 24 | $255 | — | ||
| Q4 23 | $348 | — | ||
| Q3 23 | $536 | — | ||
| Q2 23 | $428 | — | ||
| Q1 23 | $556 | — |
| Q1 24 | $-866.0K | — | ||
| Q4 23 | $-1.5M | — | ||
| Q3 23 | $-1.9M | — | ||
| Q2 23 | $-1.8M | — | ||
| Q1 23 | $-3.7M | — |
| Q1 24 | -354327.8% | — | ||
| Q4 23 | -333335.6% | — | ||
| Q3 23 | -388225.7% | — | ||
| Q2 23 | -710249.5% | — | ||
| Q1 23 | -566103.8% | — |
| Q1 24 | -339596.1% | — | ||
| Q4 23 | -445369.3% | — | ||
| Q3 23 | -358154.7% | — | ||
| Q2 23 | -413373.4% | — | ||
| Q1 23 | -667248.0% | — |
| Q1 24 | $-1.31 | — | ||
| Q4 23 | $31.30 | — | ||
| Q3 23 | $-4.90 | — | ||
| Q2 23 | $-5.21 | — | ||
| Q1 23 | $-55.20 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
